SCHEMBL10255285

SCHEMBL10255285

O=C(N1CC=C(c2cncc(-c3nnc(-c4ccccc4)o3)n2)CC1)N1CCOCC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATR Q13535 2/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
KCNH2 Q12809 1/20 0.43
HRH3 Q9Y5N1 1/20 0.43
ALDH1A1 P00352 5/20 0.43
RAB9A P51151 4/20 0.43
HSD17B10 Q99714 1/20 0.43
ACACB O00763 1/20 0.39
ACACA Q13085 1/20 0.39
MAPT P10636 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
TSHR P16473 3/20 0.38
NPC1 O15118 2/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
AKR1C3 P42330 1/20 0.38
ALOX15 P16050 1/20 0.37
GAA P10253 1/20 0.37
KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10255800 0.92 NPC1 (0.47) ATRSMN1; SMN2KCNH2HRH3ALDH1A1
SCHEMBL10255807 0.91 NPC1 (0.48) ATRSMN1; SMN2KCNH2HRH3ALDH1A1
SCHEMBL10255302 0.85 MAPT (0.40) ATRSMN1; SMN2KCNH2HRH3ALDH1A1
SCHEMBL14822724 0.85 NPC1 (0.50) ATRSMN1; SMN2ALDH1A1RAB9AMAPT
SCHEMBL614880 0.84 ATR (0.65) ATR
SCHEMBL10255367 0.84 ALDH1A1 (0.45) SMN1; SMN2ALDH1A1RAB9AMAPTTSHR
SCHEMBL10255731 0.83 NAMPT (0.46) ATRSMN1; SMN2KCNH2HRH3ALDH1A1
SCHEMBL10256651 0.83 GRM1 (0.44) ATRSMN1; SMN2ALDH1A1RAB9AMAPT
SCHEMBL10255376 0.83 MEN1 (0.45) SMN1; SMN2ALDH1A1RAB9AMAPTMEN1
SCHEMBL10255254 0.83 MEN1 (0.44) SMN1; SMN2ALDH1A1RAB9AMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8410112-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-02 US disclosed
US-20120040020-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040020-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK2, CHEK1 ATR 1/4885SMN1; SMN2 841/4885KCNH2 3467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.